Nancy A. Simonian - 06 Oct 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
President & CEO, Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
06 Oct 2022
Net transactions value
$0
Form type
4
Filing time
11 Oct 2022, 16:36:47 UTC
Previous filing
17 May 2022
Next filing
14 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +115,000 $0.000000 115,000 06 Oct 2022 Common Stock 115,000 $6.73 Direct F1
transaction SYRS Restricted Stock Units Award $0 +80,250 $0.000000 80,250 06 Oct 2022 Common Stock 80,250 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Remarks:

Exhibit 24: Power of Attorney